Emami Limited
Emami Limited (EMAMILTD.NS) Stock Competitors & Peer Comparison
See (EMAMILTD.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Household & Personal Products Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EMAMILTD.NS | ₹445.00 | -5.69% | 200.1B | 25.18 | ₹18.21 | +2.62% |
| HINDUNILVR.BO | ₹2,184.55 | -3.07% | 5.2T | 48.14 | ₹46.24 | +1.93% |
| HINDUNILVR.NS | ₹2,192.00 | -2.79% | 5.2T | 51.81 | ₹42.96 | +1.93% |
| GODREJCP.BO | ₹1,077.95 | -4.77% | 1.1T | 62.70 | ₹17.81 | +1.79% |
| GODREJCP.NS | ₹1,079.90 | -4.64% | 1.1T | 62.80 | ₹17.78 | +1.79% |
| MARICO.NS | ₹776.10 | -0.35% | 1T | 59.26 | ₹13.25 | +1.34% |
| MARICO.BO | ₹776.55 | -0.40% | 1T | 59.48 | ₹13.20 | +1.34% |
| DABUR.BO | ₹466.10 | -4.46% | 849.4B | 46.18 | ₹10.37 | +1.67% |
| DABUR.NS | ₹465.95 | -4.50% | 848.9B | 46.06 | ₹10.39 | +1.67% |
| COLPAL.NS | ₹2,160.50 | -1.82% | 599.6B | 45.27 | ₹48.70 | +2.31% |
Stock Comparison
EMAMILTD.NS vs HINDUNILVR.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, HINDUNILVR.BO has a market cap of 5.2T. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while HINDUNILVR.BO trades at ₹2,184.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas HINDUNILVR.BO's P/E ratio is 48.14. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to HINDUNILVR.BO's ROE of +0.29%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to HINDUNILVR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check HINDUNILVR.BO's competition here
EMAMILTD.NS vs HINDUNILVR.NS Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, HINDUNILVR.NS has a market cap of 5.2T. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while HINDUNILVR.NS trades at ₹2,192.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas HINDUNILVR.NS's P/E ratio is 51.81. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to HINDUNILVR.NS's ROE of +0.29%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to HINDUNILVR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check HINDUNILVR.NS's competition here
EMAMILTD.NS vs GODREJCP.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, GODREJCP.BO has a market cap of 1.1T. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while GODREJCP.BO trades at ₹1,077.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas GODREJCP.BO's P/E ratio is 62.70. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to GODREJCP.BO's ROE of +0.15%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to GODREJCP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check GODREJCP.BO's competition here
EMAMILTD.NS vs GODREJCP.NS Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, GODREJCP.NS has a market cap of 1.1T. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while GODREJCP.NS trades at ₹1,079.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas GODREJCP.NS's P/E ratio is 62.80. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to GODREJCP.NS's ROE of +0.15%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to GODREJCP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check GODREJCP.NS's competition here
EMAMILTD.NS vs MARICO.NS Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, MARICO.NS has a market cap of 1T. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while MARICO.NS trades at ₹776.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas MARICO.NS's P/E ratio is 59.26. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to MARICO.NS's ROE of +0.40%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to MARICO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check MARICO.NS's competition here
EMAMILTD.NS vs MARICO.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, MARICO.BO has a market cap of 1T. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while MARICO.BO trades at ₹776.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas MARICO.BO's P/E ratio is 59.48. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to MARICO.BO's ROE of +0.40%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to MARICO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check MARICO.BO's competition here
EMAMILTD.NS vs DABUR.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, DABUR.BO has a market cap of 849.4B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while DABUR.BO trades at ₹466.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas DABUR.BO's P/E ratio is 46.18. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to DABUR.BO's ROE of +0.17%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to DABUR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check DABUR.BO's competition here
EMAMILTD.NS vs DABUR.NS Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, DABUR.NS has a market cap of 848.9B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while DABUR.NS trades at ₹465.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas DABUR.NS's P/E ratio is 46.06. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to DABUR.NS's ROE of +0.17%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to DABUR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check DABUR.NS's competition here
EMAMILTD.NS vs COLPAL.NS Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, COLPAL.NS has a market cap of 599.6B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while COLPAL.NS trades at ₹2,160.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas COLPAL.NS's P/E ratio is 45.27. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to COLPAL.NS's ROE of +0.81%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to COLPAL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check COLPAL.NS's competition here
EMAMILTD.NS vs COLPAL.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, COLPAL.BO has a market cap of 599.3B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while COLPAL.BO trades at ₹2,149.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas COLPAL.BO's P/E ratio is 45.08. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to COLPAL.BO's ROE of +0.81%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to COLPAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check COLPAL.BO's competition here
EMAMILTD.NS vs PGHH.NS Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, PGHH.NS has a market cap of 353.3B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while PGHH.NS trades at ₹10,600.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas PGHH.NS's P/E ratio is 49.45. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to PGHH.NS's ROE of +1.01%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to PGHH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check PGHH.NS's competition here
EMAMILTD.NS vs PGHH.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, PGHH.BO has a market cap of 353.1B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while PGHH.BO trades at ₹10,658.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas PGHH.BO's P/E ratio is 49.14. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to PGHH.BO's ROE of +1.01%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to PGHH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check PGHH.BO's competition here
EMAMILTD.NS vs GILLETTE.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, GILLETTE.BO has a market cap of 263.9B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while GILLETTE.BO trades at ₹7,955.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas GILLETTE.BO's P/E ratio is 49.42. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to GILLETTE.BO's ROE of +0.58%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to GILLETTE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check GILLETTE.BO's competition here
EMAMILTD.NS vs GILLETTE.NS Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, GILLETTE.NS has a market cap of 263.8B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while GILLETTE.NS trades at ₹7,969.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas GILLETTE.NS's P/E ratio is 49.48. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to GILLETTE.NS's ROE of +0.58%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to GILLETTE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check GILLETTE.NS's competition here
EMAMILTD.NS vs EMAMILTD.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, EMAMILTD.BO has a market cap of 200.2B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while EMAMILTD.BO trades at ₹444.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas EMAMILTD.BO's P/E ratio is 25.20. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to EMAMILTD.BO's ROE of +0.29%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to EMAMILTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check EMAMILTD.BO's competition here
EMAMILTD.NS vs CUPID.NS Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, CUPID.NS has a market cap of 108.2B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while CUPID.NS trades at ₹90.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas CUPID.NS's P/E ratio is 130.58. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to CUPID.NS's ROE of +0.24%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to CUPID.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check CUPID.NS's competition here
EMAMILTD.NS vs CUPID.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, CUPID.BO has a market cap of 108.1B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while CUPID.BO trades at ₹90.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas CUPID.BO's P/E ratio is 128.85. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to CUPID.BO's ROE of +0.24%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to CUPID.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check CUPID.BO's competition here
EMAMILTD.NS vs HONASA.NS Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, HONASA.NS has a market cap of 94.6B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while HONASA.NS trades at ₹283.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas HONASA.NS's P/E ratio is 60.84. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to HONASA.NS's ROE of +0.13%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to HONASA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check HONASA.NS's competition here
EMAMILTD.NS vs HONASA.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, HONASA.BO has a market cap of 94.6B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while HONASA.BO trades at ₹283.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas HONASA.BO's P/E ratio is 60.93. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to HONASA.BO's ROE of +0.13%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to HONASA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check HONASA.BO's competition here
EMAMILTD.NS vs JYOTHYLAB.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, JYOTHYLAB.BO has a market cap of 89.8B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while JYOTHYLAB.BO trades at ₹240.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas JYOTHYLAB.BO's P/E ratio is 26.23. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to JYOTHYLAB.BO's ROE of +0.18%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to JYOTHYLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check JYOTHYLAB.BO's competition here
EMAMILTD.NS vs JYOTHYLAB.NS Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, JYOTHYLAB.NS has a market cap of 89.6B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while JYOTHYLAB.NS trades at ₹240.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas JYOTHYLAB.NS's P/E ratio is 26.22. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to JYOTHYLAB.NS's ROE of +0.18%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to JYOTHYLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check JYOTHYLAB.NS's competition here
EMAMILTD.NS vs BAJAJCON.NS Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, BAJAJCON.NS has a market cap of 48.8B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while BAJAJCON.NS trades at ₹367.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas BAJAJCON.NS's P/E ratio is 31.94. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to BAJAJCON.NS's ROE of +0.22%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to BAJAJCON.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check BAJAJCON.NS's competition here
EMAMILTD.NS vs BAJAJCON.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, BAJAJCON.BO has a market cap of 48.6B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while BAJAJCON.BO trades at ₹367.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas BAJAJCON.BO's P/E ratio is 31.94. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to BAJAJCON.BO's ROE of +0.22%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to BAJAJCON.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check BAJAJCON.BO's competition here
EMAMILTD.NS vs SHK.NS Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, SHK.NS has a market cap of 18.6B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while SHK.NS trades at ₹128.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas SHK.NS's P/E ratio is 10.92. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to SHK.NS's ROE of +0.13%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to SHK.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check SHK.NS's competition here
EMAMILTD.NS vs ALLTIME.NS Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, ALLTIME.NS has a market cap of 14.4B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while ALLTIME.NS trades at ₹208.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas ALLTIME.NS's P/E ratio is 40.29. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to ALLTIME.NS's ROE of +0.08%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to ALLTIME.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check ALLTIME.NS's competition here
EMAMILTD.NS vs BCLIND.NS Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, BCLIND.NS has a market cap of 8.2B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while BCLIND.NS trades at ₹27.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas BCLIND.NS's P/E ratio is 6.97. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to BCLIND.NS's ROE of +0.14%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to BCLIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check BCLIND.NS's competition here
EMAMILTD.NS vs KAYA.NS Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, KAYA.NS has a market cap of 4.9B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while KAYA.NS trades at ₹312.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas KAYA.NS's P/E ratio is -5.64. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to KAYA.NS's ROE of +0.62%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to KAYA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check KAYA.NS's competition here
EMAMILTD.NS vs KAYA.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, KAYA.BO has a market cap of 4.8B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while KAYA.BO trades at ₹312.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas KAYA.BO's P/E ratio is -5.61. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to KAYA.BO's ROE of +0.62%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to KAYA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check KAYA.BO's competition here
EMAMILTD.NS vs ADORMUL.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, ADORMUL.BO has a market cap of 1.3B. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while ADORMUL.BO trades at ₹135.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas ADORMUL.BO's P/E ratio is -29.80. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to ADORMUL.BO's ROE of -0.32%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to ADORMUL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check ADORMUL.BO's competition here
EMAMILTD.NS vs PCCOSMA.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, PCCOSMA.BO has a market cap of 910M. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while PCCOSMA.BO trades at ₹327.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas PCCOSMA.BO's P/E ratio is 11.35. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to PCCOSMA.BO's ROE of +0.16%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to PCCOSMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check PCCOSMA.BO's competition here
EMAMILTD.NS vs JHS.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, JHS.BO has a market cap of 786.7M. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while JHS.BO trades at ₹8.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas JHS.BO's P/E ratio is -9.89. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to JHS.BO's ROE of -0.03%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to JHS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check JHS.BO's competition here
EMAMILTD.NS vs JHS.NS Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, JHS.NS has a market cap of 770.4M. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while JHS.NS trades at ₹8.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas JHS.NS's P/E ratio is -14.29. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to JHS.NS's ROE of -0.03%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to JHS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check JHS.NS's competition here
EMAMILTD.NS vs STDSFAC.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, STDSFAC.BO has a market cap of 433.5M. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while STDSFAC.BO trades at ₹51.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas STDSFAC.BO's P/E ratio is N/A. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to STDSFAC.BO's ROE of N/A. Regarding short-term risk, EMAMILTD.NS is less volatile compared to STDSFAC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check STDSFAC.BO's competition here
EMAMILTD.NS vs AMBICAAGAR.NS Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, AMBICAAGAR.NS has a market cap of 415.3M. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while AMBICAAGAR.NS trades at ₹24.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas AMBICAAGAR.NS's P/E ratio is 32.68. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to AMBICAAGAR.NS's ROE of +0.01%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to AMBICAAGAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check AMBICAAGAR.NS's competition here
EMAMILTD.NS vs AMBICAAGAR.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, AMBICAAGAR.BO has a market cap of 413.8M. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while AMBICAAGAR.BO trades at ₹24.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas AMBICAAGAR.BO's P/E ratio is 83.07. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to AMBICAAGAR.BO's ROE of +0.01%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to AMBICAAGAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check AMBICAAGAR.BO's competition here
EMAMILTD.NS vs NKIND.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, NKIND.BO has a market cap of 383.7M. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while NKIND.BO trades at ₹66.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas NKIND.BO's P/E ratio is -6.20. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to NKIND.BO's ROE of +0.02%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to NKIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check NKIND.BO's competition here
EMAMILTD.NS vs NKIND.NS Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, NKIND.NS has a market cap of 372.6M. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while NKIND.NS trades at ₹60.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas NKIND.NS's P/E ratio is -6.02. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to NKIND.NS's ROE of +0.02%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to NKIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check NKIND.NS's competition here
EMAMILTD.NS vs NUWAY.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, NUWAY.BO has a market cap of 354.6M. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while NUWAY.BO trades at ₹37.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas NUWAY.BO's P/E ratio is 14.40. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to NUWAY.BO's ROE of N/A. Regarding short-term risk, EMAMILTD.NS is more volatile compared to NUWAY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check NUWAY.BO's competition here
EMAMILTD.NS vs PAOS.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, PAOS.BO has a market cap of 330.5M. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while PAOS.BO trades at ₹51.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas PAOS.BO's P/E ratio is -17.08. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to PAOS.BO's ROE of +0.22%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to PAOS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check PAOS.BO's competition here
EMAMILTD.NS vs SATTVASUKU.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, SATTVASUKU.BO has a market cap of 280M. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while SATTVASUKU.BO trades at ₹0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas SATTVASUKU.BO's P/E ratio is -73.00. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to SATTVASUKU.BO's ROE of +0.12%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to SATTVASUKU.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check SATTVASUKU.BO's competition here
EMAMILTD.NS vs PARMCOS-B.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, PARMCOS-B.BO has a market cap of 169.9M. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while PARMCOS-B.BO trades at ₹34.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas PARMCOS-B.BO's P/E ratio is 166.67. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to PARMCOS-B.BO's ROE of +0.00%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to PARMCOS-B.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check PARMCOS-B.BO's competition here
EMAMILTD.NS vs HIPOLIN.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, HIPOLIN.BO has a market cap of 156.8M. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while HIPOLIN.BO trades at ₹50.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas HIPOLIN.BO's P/E ratio is -5.01. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to HIPOLIN.BO's ROE of -0.35%. Regarding short-term risk, EMAMILTD.NS is less volatile compared to HIPOLIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for EMAMILTD.NS.Check HIPOLIN.BO's competition here
EMAMILTD.NS vs CORNE.BO Comparison March 2026
EMAMILTD.NS plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EMAMILTD.NS stands at 200.1B. In comparison, CORNE.BO has a market cap of 50.2M. Regarding current trading prices, EMAMILTD.NS is priced at ₹445.00, while CORNE.BO trades at ₹9.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EMAMILTD.NS currently has a P/E ratio of 25.18, whereas CORNE.BO's P/E ratio is -5.91. In terms of profitability, EMAMILTD.NS's ROE is +0.29%, compared to CORNE.BO's ROE of +0.16%. Regarding short-term risk, EMAMILTD.NS is more volatile compared to CORNE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for EMAMILTD.NS.Check CORNE.BO's competition here